FDA Approves Erivedge (Vismodegib) for Metastatic or Locally Advanced Basal Cell Carcinoma

Pages: 4 Published: February 01, 2012 Report Code: GDHC0058VPT

  • Overview
  • Contents
  • Tables
  • Figures
  • Listen
    iSpeech

GlobalData, the industry analysis specialist, has released its new view point, “FDA Approves Erivedge (vismodegib) for Metastatic or Locally Advanced Basal Cell Carcinoma”. The report is an essential source of information on the approval of Erivedge by the US FDA. The report also provides insights on the epidemiology, etiology and current treatment options for metastatic basal cell carcinoma (BCC).

Scope

The report provides information on the epidemiology, etiology and current treatment options for BCC, potential drivers and barriers of BCC therapeutics market, approval status of Erivedge together with the review of the market potential of Erivedge.

Reasons to Buy

The report will enhance your decision making capability. It will allow you to:

To understand the epidemiology and patient flow in BCC therapeutic market.

To understand the unmet need of the BCC therapeutics market.

To review the drivers and barriers of BCC therapeutics market.

To understand the mode of action and approval status of Erivedge in the US, Europe and Japan.

Table of Contents

1 Table of Contents

1.1 List of Figures

2 Summary

3 FDA Approves Erivedge (Vismodegib) for Metastatic or Locally Advanced Basal Cell Carcinoma

3.1 Disease Overview

3.1.1 Nodular BCC

3.1.2 Ulcerating BCC

3.1.3 Pigmented BCC

3.1.4 Sclerosing BCC

3.1.5 Gorlin-Goltz Syndrome

3.2 Epidemiology

3.3 Current Therapy Options

3.3.1 Surgical Management

3.3.2 Non-Surgical Management

3.4 Unmet Need

3.5 Drivers and Barriers

3.5.1 Drivers

3.5.2 Barriers

3.6 Erivedge (vismodegib)

3.6.1 Clinical Study Details

3.6.2 Dosage and Pricing of Erivedge

3.6.3 Market Potential of Erivedge

4 Appendix

4.1 Methodology

4.1.1 Coverage

4.1.2 Secondary Research

4.1.3 Primary Research

4.1.4 Expert Panel Validation

4.2 Contact Us

4.3 Disclaimer

List of Tables

N/A

List of Figures

Figure 1: Types of Skin Cancer

Figure 2: Histology – Sclerosing and Nodular BCC

$500

Can be used by individual purchaser only

$1500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.